Completed PHASE3 INTERVENTIONAL 2-arm NCT02711163

Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula (ALYCE)

Evaluation of the Hypoallergenicity of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow's Milk Protein Allergy

Sponsor: United Pharmaceuticals

Conditions Cow Milk Allergy

Interventions Amino acid formula Extensively Hydrolyzed formula

Updated 5 times since 2017 Last updated: May 14, 2018 Started: Apr 30, 2016 Primary completion: Aug 31, 2017 Completion: Nov 29, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cow Milk Allergy and is currently completed. United Pharmaceuticals leads this study, which shows 5 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

United Pharmaceuticals

Data source: United Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roma, Italy